Azitra Q3 net loss narrows to $1.0M; pipeline advances with ATR-12 dosing, ATR-04 IND clearance

Azitra, Inc.

2024-Q3 EPS reported -$2.64 revenue$7,500

Net loss of $1.0M in Q3 2024 vs $1.9M in Q3 2023; cash and equivalents $7.3M as of Sept 30, 2024.
R&D expenses rose to $1.0M from $0.5M; G&A steady at $1.9M; service revenue was $0 vs $310K.
Completed $10M follow-on offering; dosed first Netherton syndrome patient with ATR-12 in Phase 1b trial.
Received IND clearance and Fast Track designation from FDA for ATR-04 to treat EGFRi-associated rash.
Anticipates initial safety data from ATR-12 trial in Q1 2025; first ATR-04 patient dosed in Q1 2025; topline data YE 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.